Biotech Daily's February 2nd report had an update whether KV's problems would affect Evamist.
http://www.biotechdaily.com.au/media/backissues/2009%20February/BD%20Biotech%20Daily%20February%202.pdf
Separately, Dr Treagus told Biotech Daily that quality and manufacturing problems facing KV Pharmaceuticals was not having an impact on sales marketing and distribution of Acrux's Evamist, known as Ellavie outside the US, to treat menopause symptoms. Dr Treagus said KV's problems were with manufacturing and Evamist was manufactured by a third party pharmaceutical company in Texas, with KV providing sales, marketing and distribution.
He said that Evamist was a silver lining on KV's black cloud, allowing KV to more closely focus on his company's product.
"There has been no disruption to the manufacturing and supply and KV continues to market and supply Evamist," Dr Teagus said. "Evamist is not caught up in this."
"Under certain circumstances we could reacquire the rights to our product, but they continue to market and sell our product," Dr Treagus said.
There's nothing on the effects on the development of the six other products Acrux has partnered with KV, but perhaps the bit about reacquisition of rights suggests an option if KV can't properly fund their development.
Add to My Watchlist
What is My Watchlist?
